Patent · US Active

TLR7/8 antagonists and uses thereof

US11512069B2 · kind B2 · utility

0Cited by

15References

6Claims

0Family size

Assignee

Merck Patent GmbH · DE

Inventors

Brian A. Sherer · Nashua, US
Xiaoling Chen · Sharon, US
Esther Cleary · Somerville, US
Nadia Brugger · Cambridge, US

Key dates

Filing date	Sep 18, 2020
Grant date	Nov 29, 2022
Priority date	—
Expiry date	Nov 9, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D487/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A method of administering to a patient in need thereof or contacting with a biological sample, a compound related to Formula I-e or pharmaceutically acceptable compositions thereof, is useful to inhibit activity of TLR7/8 or a mutant thereof and/or to treat a TLR7/8-mediated disorder.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.